In May 2020, Distributed Bio, and their therapeutics spin-out company Centivax, announced that three independent laboratories have confirmed that multiple Centivax antibody therapeutic candidates are potent neutralizers of the pandemic coronavirus. Viral neutralization directly demonstrates that the antibodies are able to completely block the novel coronavirus from infecting human cells.
How, exactly, was this achieved?
Attend this webinar to learn step by step how two technologies, the SuperHuman antibody library and Tumbler antibody optimization technology enabled this scientific achievement.
Jake Glanville and Sarah Ives will illustrate how the SuperHuman discovery technology was used to rapidly discover novel, fully human, high affinity, thermostable, SARS-CoV-2 neutralizing antibodies from a computationally optimized, fully human library comprised of ~76 billion sequence-unique antibodies. In just 4 weeks, they identified potent, novel therapeutics against the viral spike protein including broad-spectrum antibodies that bind tightly to and block both SARS and SARS-CoV-2.
They will also discuss how Distributed Bio’s Tumbler optimization technology was used to adapt 5 previously proven potently neutralizing and protective anti-SARS antibodies to target the novel pandemic COVID19-causing SAR-CoV-2 coronavirus. These well-established, super-potent anti-SARS antibodies could neutralize SARS and completely protect animals from SARS.
In addition to high affinity and potent neutralization, the antibodies have been engineered for optimal therapeutic properties, features built in to the SuperHuman design and Tumbler engineering process. These antibodies represent the cutting edge of modern antibody engineering. They are optimized for enhanced potency, thermostability, reduced immunogenicity, extended half-life, and enhanced safety. This makes them ideal therapeutic candidates for treating the novel pandemic coronavirus in both the hospital as well as prophylactic settings.
Find out how the SuperHuman and Tumbler technologies can be applied to accelerate your therapeutic programs. This webinar will include a case study, expert panel discussion and live Q&A.
Webinar Presenters & Panelist
Jake Glanville, PhD
Founding Partner, Chief Executive Officer, President, Chairman of the Board
Director of Contract Research
Katherine Vousden, PhD
Science Director, Large Molecules
Have a scheduling conflict? Sign up even if you can't make it; we'll share the recording after.
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.